Karolinska Development (KD) is an early-stage, publicly-listed Nordic venture capital firm focusing on the life sciences industry.
KD invests in Nordic companies developing potentially ground-breaking treatments to relieve or cure serious diseases. Innovation level is an important parameter in evaluating the commercial potential of life science projects. KD focuses on projects that are based on new types of compounds or technologies with the potential to dramatically improve patients’ quality of life and maybe even increase the chances of a cure and survival.
Its current portfolio includes:
invoX strategic investment
In October 2021, Sino Biopharmaceutical transferred its holding in Karolinska Development (KD) to the wholly-owned subsidiary invoX. invoX further increased its shareholding to 47.67% with Karolinska Development concluding a rights issue in February 2022.Visit Karolinska Development website